Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

13:42
01/17/18
01/17
13:42
01/17/18
13:42
Recommendations
Juno Therapeutics, Celgene analyst commentary  »

Celgene acquisition of…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

12:18
01/17/18
01/17
12:18
01/17/18
12:18
General news
On The Fly: Top stock stories at midday »

Stocks opened sharply…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

BLUE

bluebird bio

$163.35

-7.35 (-4.31%)

CLLS

Cellectis

$27.78

-1.54 (-5.25%)

BLCM

Bellicum Pharmaceuticals

$8.46

-0.5 (-5.58%)

BAC

Bank of America

$31.10

-0.145 (-0.46%)

GS

Goldman Sachs

$253.49

-4.97 (-1.92%)

GT

Goodyear Tire

$33.50

-0.41 (-1.21%)

PSTG

Pure Storage

$17.87

1.71 (10.58%)

F

Ford

$12.23

-0.8684 (-6.63%)

FAST

Fastenal

$55.44

-0.15 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 18

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 31

    Jan

  • 15

    Feb

  • 16

    Feb

  • 26

    Feb

  • 14

    Mar

  • 25

    Mar

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

11:29
01/17/18
01/17
11:29
01/17/18
11:29
Downgrade
Juno Therapeutics, Celgene rating change at Wedbush »

Wedbush says 'hard…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

11:22
01/17/18
01/17
11:22
01/17/18
11:22
Downgrade
Juno Therapeutics rating change at Wedbush »

Juno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

10:43
01/17/18
01/17
10:43
01/17/18
10:43
Hot Stocks
Juno, CAR-T peers rise after report of potential Celgene deal »

Shares of Juno…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

GILD

Gilead

$80.25

1.23 (1.56%)

BLUE

bluebird bio

$163.35

-7.35 (-4.31%)

BLCM

Bellicum Pharmaceuticals

$8.46

-0.5 (-5.58%)

CLLS

Cellectis

$27.78

-1.54 (-5.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 12

    Feb

  • 16

    Feb

  • 26

    Feb

  • 25

    Mar

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

10:20
01/17/18
01/17
10:20
01/17/18
10:20
Options
Call spread in Juno as shares rally »

Call spread in Juno as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

08:16
01/17/18
01/17
08:16
01/17/18
08:16
Recommendations
Juno Therapeutics, Celgene, Acquired by GILD 9/17 analyst commentary at Leerink »

Celgene possible…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

KITE

Acquired by GILD 9/17

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

07:42
01/17/18
01/17
07:42
01/17/18
07:42
Recommendations
Juno Therapeutics, Celgene analyst commentary at Wells Fargo »

Juno Therapeutics price…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

CELG

Celgene

$104.82

-1.18 (-1.11%)

, JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

05:45
01/17/18
01/17
05:45
01/17/18
05:45
Recommendations
Celgene, Juno Therapeutics analyst commentary at Jefferies »

Jefferies believes $8B…

CELG

Celgene

$104.82

-1.18 (-1.11%)

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

Yesterday
JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

20:38
01/16/18
01/16
20:38
01/16/18
20:38
Recommendations
Juno Therapeutics, Celgene, Acquired by GILD 9/17, Gilead analyst commentary at Citi »

Juno could be worth $110…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

KITE

Acquired by GILD 9/17

GILD

Gilead

$80.25

1.23 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 12

    Feb

  • 16

    Feb

  • 25

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.